Multiple variables were proved to be significantly linked to the PFS of NSCLC patients with ICI treatment, including ERBB4 mutation (p = 0.0079), EGFR mutation (p = 0.0152), smoking (p = 0.0040), treatment lines (p = 0.0097), TMB (p = 0.0059), and PD-L1 expression (p = 0.0113) (Fig. 3A–F). This evidence concerns the gene CD274 and non-small cell lung carcinoma.